H eart failure can often result from chronic neurohormonal and mechanical stress and remains a leading cause of death worldwide. The mineralocorticoid receptor (MR), a steroid receptor for corticosteroids, plays a pathophysiological role in the development of heart failure. High circulating levels of MR ligands were reportedly associated with poor prognosis in patients with heart failure, 1 whereas recent clinical trials of cardiac dysfunction showed beneficial effects of MR blockade on morbidity and mortality. [2][3][4] Although the aldosterone-MR system was conventionally associated with renal sodium absorption in the distal tubules, experimental studies have revealed a direct effect of aldosterone on the heart and a pathological role of MR in the myocardium. Aldosterone excess or MR activation in the myocardium leads to unfavorable responses, including hypertrophy, 5 fibrogenic signaling, 6 and arrhythmogenic changes.
H eart failure can often result from chronic neurohormonal and mechanical stress and remains a leading cause of death worldwide. The mineralocorticoid receptor (MR), a steroid receptor for corticosteroids, plays a pathophysiological role in the development of heart failure. High circulating levels of MR ligands were reportedly associated with poor prognosis in patients with heart failure, 1 whereas recent clinical trials of cardiac dysfunction showed beneficial effects of MR blockade on morbidity and mortality. [2] [3] [4] Although the aldosterone-MR system was conventionally associated with renal sodium absorption in the distal tubules, experimental studies have revealed a direct effect of aldosterone on the heart and a pathological role of MR in the myocardium. Aldosterone excess or MR activation in the myocardium leads to unfavorable responses, including hypertrophy, 5 fibrogenic signaling, 6 and arrhythmogenic changes. 7, 8 Furthermore, MR ablation in cardiomyocytes was shown to attenuate cardiac dysfunction in a mouse model of myocardial infarction 9 and chronic pressure overload. 10 The mechanism for MR activation in cardiac injury remains unclear. Although ligand excess is an important stimulus, aberrant MR activation can occur with a normal or even low aldosterone status in some pathological conditions, leading to end-organ damage. Indeed, Dahl salt-sensitive rats fed a high-salt diet develop cardiac injury with enhanced MR signaling, despite low levels of circulating aldosterone, whereas eplerenone dramatically retards progression of cardiac remodeling. 11 Recently, several studies have suggested that MR activity is also affected by factors other than its ligands. [12] [13] [14] We previously identified Rac1, a Rho family small GTPase, as a novel modulator of MR activity and demonstrated the pathological role of Rac1-mediated MR activation in the kidney of proteinuric disease 15 and salt-sensitive hypertension.
In the present study, we found that Rac1 mediates MR activation in the myocardium, which leads to cardiac dysfunction by recruitment of the responsible isoform of NADPH oxidase, NOX4, in pressure overload-induced heart failure.
Methods
Methods are available in the online-only Data Supplement.
Animals and Experimental Design
All animal procedures were approved by the Animal Care Committee of The University of Tokyo. Chronic pressure overload induced by transverse aortic constriction (TAC) surgery was performed as previously described 19 using a 27-gauge needle. In the drug treatment study, 9-week-old male C57BL/6J mice (Tokyo Laboratory Animals Sciences, Tokyo, Japan) were infused with NSC23766 (Tocris Biosciences, Bristol, UK; at a dose of 15 mg/ kg/d) via an osmotic minipump (Alzet, Palo Alto, CA) starting from 7 days before TAC surgery or fed eplerenone (Pfizer, New York, NY; 1.25 g/kg, in chow) from 3 days after TAC surgery. NSC23766 is a selective small-molecule Rac1 inhibitor, which inhibits the activation of Rac1 by hindering its binding to the Rac-specific guanine nucleotide exchange factors without altering the access of the related RhoA or Cdc42 to their specific guanine nucleotide exchange factors. 20, 21 A similar dose of NSC23766 used in our previous report reduced Rac1 activity in the kidney without apparent evidence of organ toxicity in mice. 15 Cardiomyocyte-specific Rac1-deficient mice were generated by crossing Rac1-floxed mice 22 on C57BL/6J background with transgenic mice expressing Cre recombinase under control of α-myosin heavy chain promoter (Myh6-cre) 23 ,24 on a C57BL/6J background. In the Rac1-floxed mice, the loxP site is inserted to delete the entire exon 1 of the Rac1 gene as previously described. 22 (Table S2 and S3 in the online-only Data Supplement).
Statistical Analysis
Data are expressed as mean±SEM. We used an unpaired t test for comparisons between the 2 groups. For multiple comparisons, we used analysis of variance with the Tukey-Kramer post hoc test. A P value <0.05 was considered statistically significant.
Results

Pharmacological Inhibition of Rac1 Abolished MR Activation in the Pressure-Overloaded Heart and Subsequent Cardiac Hypertrophy and Dysfunction
To clarify the role of Rac1-evoked MR activation in cardiac injury, we performed an in vivo study using a mouse model of TAC. In our experiment, chronic pressure overload induced by TAC resulted in cardiac hypertrophy at 2 weeks of treatment, which was followed by gradually developing cardiac dysfunction 7 weeks later. Two weeks after surgery, the expression of activated form of Rac1 protein was significantly increased in the pressure-overloaded heart, without any change in the total amount of Rac1 protein, indicating Rac1 activation ( Figure  S1A ). As reported previously, 25 MR protein was mainly located in the nuclear fraction rather than in cytosol in the heart at steady state ( Figure S1B ). Nuclear accumulation of MR started to increase in the pressure-overloaded heart during the early period (2 weeks after treatment), suggesting MR activation ( Figure S1C ).
The Rac1 activation induced by TAC persisted during the 7-week treatment ( Figure 1A ), which was accompanied by further increased accumulation of nuclear MR ( Figure 1B) . Consistent with MR activation, gene expression of plasminogen activator inhibitor-1 (Serpine1) and the serine (or cysteine) peptidase inhibitor, clade A, member 3 N (Serpina3n), which are downstream targets of MR in cardiomyocytes, was upregulated in pressure-overloaded hearts ( Figure 1C ), despite slightly, but not significantly, elevated circulating aldosterone and unchanged corticosterone levels (Table S1 ).
To clarify the relationship between Rac1 activity and MR signaling, we evaluated the effects of pharmacological intervention with the Rac1 inhibitor NSC23766 or the MR blocker eplerenone on the TAC-induced changes. Treatment with NSC23766 inhibited TAC-induced activation of Rac1 ( Figure 1A ) and was associated with a significant reduction in MR signaling ( Figure 1B and 1C) , without altering the levels of ligands (Table S1 ). This inhibition of MR signaling by the Rac1 inhibitor is consistent with the result of treatment with eplerenone, a selective MR antagonist ( Figure 1B and 1C). These findings suggest that cardiac Rac1 stimulated by pressure overload induces MR activation in a ligand-independent manner, as previously reported in renal diseases. [14] [15] [16] [17] Next, we examined the impact of pharmacological intervention of the Rac1-MR pathway on TAC-induced cardiac injury. A 7-week TAC treatment markedly increased the size of cardiomyocytes and heart weight and reduced ejection fraction in the left ventricle (Figure 2A-2E; Table S1 ), with increased gene expression of atrial natriuretic peptide (Nppa) and β-myosin heavy chain (Myh7), which are markers of pathological hypertrophy in the myocardium ( Figure 2F ). Both the TAC-induced cardiac hypertrophy and dysfunction were significantly attenuated by treatment with NSC23766 or eplerenone ( Table S1 ). Overall, these findings suggest that Rac1-mediated MR activation is involved in the pathogenesis of cardiac hypertrophy and dysfunction in the pressure-overloaded heart.
Rac1-MR Pathway Was Associated With Nox4-Related Reactive Oxygen Species Production in the Pressure-Overloaded Heart
To further investigate the underlying mechanism linking the Rac1-MR pathway and heart failure, we assessed reactive oxygen species (ROS) generation and its major source of NADPH oxidase activity because of their reported association with Rac1 26,27 and MR 9, 11, 28 in cardiac injury. We found that pressure overload markedly increased the amount of 4-hydroxy-2-nonenal, a cytotoxic lipid peroxidation product, and NADPHdependent O 2 − production. These were suppressed by either NSC23766 or eplerenone ( Figure 3A and 3B).
Nox2 and Nox4, the major isoforms in the myocardium, 29, 30 play different roles in cardiac injury. Recent experiments demonstrated that Nox4, 31, 32 but not Nox2, 33 is the isoform responsible for pressure overload-induced cardiac injury. Consistently, in the current study, gene expression of Nox4 markedly increased in the pressure-overloaded heart, which was attenuated by either NSC23766 or eplerenone ( Figure 3C ), implying that the Rac1-MR pathway is involved in Nox4 gene regulation. However, neither treatment altered Cybb (Nox2) gene expression ( Figure 3C ).
Heterozygous Deletion of Rac1 in Cardiomyocytes Confirmed the Role of Rac1-MR Pathway in Pressure Overload-Induced Cardiac Injury
To confirm that myocardial Rac1 serves as a modulator of aberrant MR activation in the pressure-overloaded heart, we generated cardiomyocyte-specific heterozygous Rac1-deficient mice by crossing Rac1-floxed mice 22 with Myh6-cre transgenic mice. WT mice ( Figure S2E ). Next, we applied Sham or TAC to Rac1 CM+/− and Rac1 WT mice. Seven weeks after surgery, TAC increased the amount of active Rac1 and MR signaling in the left ventricle in Rac1 WT mice, whereas these abnormalities were significantly attenuated in Rac1 CM+/− mice ( Figure 4A-4C ). These results support the hypothesis that myocyte-Rac1 is involved in the aberrant activation of MR in the pressureoverloaded heart. Furthermore, TAC-induced NADPHdependent O 2 − production and Nox4 gene expression were suppressed in Rac1 CM+/− mice compared with Rac1 WT mice ( Figure 4C and 4D) .
With the suppression of Rac1-MR signaling and the resulting reduction in Nox4-related ROS production, the hearts of Rac1 CM+/− mice were protected against TAC-induced hypertrophy and dysfunction. After 7 weeks of TAC, either the increase in heart weight and size of cardiomyocytes or the induction of Nppa and Myh7 genes were ameliorated in Rac1 CM+/− mice (Figure 5C and 5D ; Tables S2 and S3) following NSC23766 and eplerenone treatment ( Figure 2D ), which was associated with improvement of ejection fraction (Figure 5A and 5B; Table S3 ). Finally, the results of hemodynamic analysis in the left ventricle clearly showed a protective effect of cardiomyocyte-specific Rac1 deletion on TAC-induced cardiac dysfunction ( Figure 5E ).
Discussion
In this study, we observed that chronic pressure overload activated Rac1, and in turn, Rac1 activation increased nuclear accumulation of MR protein and the expression of MR target genes in mice hearts. In addition to systemic MR blockade, both pharmacological Rac1 inhibition and heterozygous deletion of Rac1 in cardiomyocytes abolished TAC-induced MR activation, resulting in attenuated cardiac hypertrophy and dysfunction, along with reduced TAC-induced ROS overproduction and expression of Nox4 gene. These findings suggest a pathological role of Rac1-mediated MR activation in the failing heart.
Although several studies have revealed a pathological role of myocardial MR in heart failure, the mechanism of MR activation in the failing heart remains unclear. In tubular epithelial cells of the classical aldosterone-sensitive distal nephron, where 11β-HSD2 protects MR from cortisol, MR is located mainly in the cytoplasm and is translocated to the nucleus on aldosterone binding. On the other hand, in nonepithelial tissues like the myocardium, where the expression of 11β-HSD2 is low or undetectable, 34 the MR is supposedly saturated with abundantly circulating cortisol. 13 Hernández-Díaz et al reported that myocardial MR was mainly localized in the nucleus, regardless of circulating corticosteroid levels. 25 However, it is unclear whether the nuclear accumulation of MR in the heart changes in pathological conditions.
In the present study, we found that nuclear accumulation of MR was further promoted in the pressure-overloaded heart, indicating aberrant MR activation. Moreover, the Rac1 inhibitor NSC23766 and heterozygous deletion of Rac1 in cardiomyocytes suppressed this response without affecting the level of circulating ligands, suggesting that activated Rac1 in the myocardium mediates MR activation in the failing heart in a ligand-independent fashion. These findings are compatible with our previous observation in cultured cardiomyocytes that overexpression of active Rac1 induced MR activation in a ligand-independent manner in cells cultured with serum-depleted medium or when the cellular MR gene was replaced with a ligand-resistant mutant. 18 Given that the ligand binding of MR in cardiomyocytes is already saturated at steady state by the absence of 11β-HSD2, Rac1 serves as an enhancer of MR activation via increased nuclear MR translocation in the pressure-overloaded heart, in a similar manner to the essential role for Rac1 in the nuclear localization of β-catenin, a transcription factor involved in canonical Wnt signaling. 35 Aberrant Rac1-mediated MR activation in the myocardium was supported by changes in the expression of various target genes of MR in the myocardium. Fejes-Tóth et al identified various genes, including Serpine1, as potential targets of the aldosterone-MR system in a cardiomyocyte cell line stably expressing MR. 36 In addition, Latouche et al recently indicated that Serpine1 and Serpina3n genes were MR targets in the myocardium using mice with cardiomyocyte-specific overexpression of MR or glucocorticoid receptor. 37 In the present study, gene expression of Serpine1 and Serpina3n was upregulated in parallel with Rac1 activation and the subsequent nuclear accumulation of MR in the pressure-overloaded heart, both of which were suppressed by either systemic or local inhibition of Rac1. The TAC-induced expression of these genes was also abolished by MR antagonists, along with the blockade of nuclear MR accumulation. Furthermore, all of these interventions targeted at the Rac1-MR pathway ameliorated cardiac dysfunction, which indicates the involvement of Rac1-mediated MR activation in the development of TACinduced heart failure.
With regard to the NADPH oxidases involved in the development of heart failure, the 2 major isoforms of NADPH oxidase in cardiomyocytes, Nox2 and Nox4, have markedly different properties in terms of regulation and subcellular localization. Nox2 activation requires stimulusinduced membrane translocation of cytosolic regulatory subunits, including Rac1. 38 Using cardiomyocyte-specific Rac1-deficient mice, several studies have reported a pathological role of Rac1 participating in Nox2 activation in angiotensin II-induced cardiac injuries. 26 By contrast, Nox4 (Table S3) is distributed on the membranes of mitochondria and in the nuclei of cardiomyocytes, 29, 31, 32 and constitutively generates O 2 − to locally regulate ROS generation. 39, 40 It should be noted that Nox2-deletion failed to attenuate TAC-induced cardiac injury, 33 although it showed a protective effect on angiotensin II-induced hypertrophy and remodeling. 30 By contrast, cardiomyocyte-specific deletion of Nox4 attenuated pressure overload-induced cardiac hypertrophy and dysfunction by reducing local ROS overgeneration in mitochondria and nuclei. 31, 32 Consistent with the results of several studies demonstrating the association of Nox4 in MR-related cardiac injuries, 9,41 our study showed that Nox4 gene induction by pressure overload was suppressed by all 3 interventions targeting the Rac1-MR pathway, in association with improvement in cardiac dysfunction. Taken together, these findings suggest that Rac1 serves as an activator of MR, a nuclear transcriptional factor, which is distinct from the classical role of Rac1 in Nox2 activation, and that Rac1-MR pathway activation plays a critical role in increased Nox4 gene transcription and the resulting cardiac dysfunction in the pressure-overloaded heart.
It should be noted that both myocyte MR and nonmyocyte MR may play a role in the development of heart failure. Indeed, genetic ablation of myeloid-MR attenuated cardiac injury induced by TAC, 42 L-NAME/angiotensin II, 43 and DOCA/salt. 44 In addition, recent studies suggest a role of endothelial MR in leukocyte adhesion in human coronary artery disease 45 and endothelial proliferation and angiogenesis in a TAC model. 46 Moreover, endothelial cell-specific MR-deficient mice are protected against DOCA/saltinduced cardiac injury, 47 suggesting the possible involvement of endothelial MR in cardiac injury. However, the role of endothelial Rac1-MR pathway in heart failure remains unknown. Given the lack of aldosterone rise in plasma by the Rac1 inhibitor in contrast to the MR antagonist, cardiac Rac1 was activated in response to TAC but adrenal Rac1 might not be affected by TAC. Moreover, several investigators demonstrated the different response of Rac1 to certain stimuli in the individual tissues: the opposite response of Rac1 activation by mechanical stretch in endothelial cells and vascular smooth muscle cells. 48 Further studies are required to clarify whether the nonmyocyte Rac1-MR pathway is involved in the development of TAC-induced heart failure.
In summary, we found that TAC-induced Rac1 activation induced aberrant MR activation in the myocardium, which leads to cardiac dysfunction via recruitment of the responsible NADPH oxidase, NOX4, in the pressure-overloaded heart. Our results suggest that the Rac1-MR-NOX4 pathway may be an alternative therapeutic target for the treatment of heart failure.
Perspectives
MR activation plays a crucial role in the pathogenesis of cardiovascular diseases, and MR blockade is now a standard strategy in the treatment of heart failure. In the present study and others, the beneficial effects of Rac1 inhibition were comparable to MR blockade in both rodent models of cardiac disease and chronic kidney disease, regardless of the levels of plasma aldosterone. Thus, Rac1 inhibition may be an alternative target to MR blockade for the treatment of heart failure and chronic kidney disease. However, given the diverse biological effects of Rac1, including activation of NOX2, a NADPH oxidase, Rac1 inhibitors may be superior to MR blockers in models of heart failure other than TAC. Thus, a suitable dose of Rac1 inhibitor could protect from heart failure by inhibition of both MR activity and NOX2-ROS production, with a reduced incidence of hyperkalemia. Further studies are required to evaluate the roles of MR-independent Rac1 signaling in various models of heart failure. 47 What Is New?
• Rac1 mediates aberrant mineralocorticoid receptor (MR) activation in the pressure-overloaded heart.
• Rac1-MR pathway activation causes cardiac injury via recruitment of NADPH oxidase 4-related reactive oxygen species overproduction.
What Is Relevant?
• The findings provide novel insight into the mechanism of MR activation in heart failure and suggest Rac1 as a potential therapeutic target in hypertensive cardiac diseases.
Summary
We provide novel evidence that Rac1 causes MR activation in the pressure-overloaded heart and that Rac1-MR activation induces cardiac injury via induction of NADPH oxidase 4. These findings indicate an important role of the Rac1-MR pathway in the pressure-overloaded heart and suggest that Rac1 may be a therapeutic target in hypertensive cardiac diseases.
